[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrophic-gastritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrophic-gastritis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,67,91,123,143,163,186,205,234],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100637944","ai-based-risk-prediction-model-for-upper-digestive-tract-cancer-100637944",false,"NCT07605312","AI-Based Risk Prediction Model for Upper Digestive Tract Cancer","Development of Artificial Intelligence Risk Prediction Model for Upper Digestive Tract Cancer Using High Resolution Endoscopic Image, Digital Pathology, Genetics, and Oro-gastro-intestinal Microbiota.","Inclusion Criteria:\n\n* Patients undergoing upper gastrointestinal endoscopy.\n* Patients with at least one of the following conditions or indications:\n\n  * Previous or current Helicobacter pylori infection (confirmed by serology, histopathology, urea breath test, rapid urease test, or stool antigen test);\n  * Dyspeptic symptoms;\n  * Gastroesophageal reflux disease;\n  * History of oral, oropharyngeal, or hypopharyngeal squamous cell carcinoma;\n  * Barrett's esophagus;\n  * Gastric premalignant lesions (intestinal metaplasia or atrophic gastritis);\n  * Gastric subepithelial lesions.\n\nExclusion Criteria:\n\n\\-",true,"ALL","40 Years",{"count":20,"type":21},10000,"ESTIMATED","10 Years","OBSERVATIONAL","Upper digestive tract cancers are often preceded by pre-malignant lesions, but there is limited evidence regarding optimal risk prediction models and screening strategies for disease progression and cancer development. This prospective multicenter cohort study aims to establish a longitudinal database integrating clinical information, endoscopic findings, pathology, genetics, epigenetics, and gastrointestinal microbiota data from subjects undergoing upper digestive tract endoscopy.\n\nThe study will develop explainable artificial intelligence (AI)-based risk prediction models to identify factors associated with disease progression, treatment response, and cancer development. Participants will be followed longitudinally to evaluate changes in lesion severity and clinical outcomes.",[26,27,28,29,30,31],"Gastric Cancer (GC)","Premalignant Lesion","Gastric Intestinal Metaplasia","Atrophic Gastritis","Dysplasia Stomach","Esophageal Cancer (EsC)","NOT_YET_RECRUITING","2026-05-25",{"date":35,"type":36},"2026-05-28","ACTUAL",{"date":38,"type":21},"2026-05-18",{"date":40,"type":21},"2030-05-18",{"name":42,"class":43},"National Taiwan University Hospital","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100622810","natural-history-evolution-and-clinical-features-of-autoimmune-atrophic-gastritis-100622810","NCT07388459","Natural History, Evolution, and Clinical Features of Autoimmune Atrophic Gastritis","NH-GAA","Inclusion Criteria:\n\n* Male or female, age ≥18 years;\n* AAG diagnosis is made according to the updated Sydney System criteria referring to a tertiary outpatient clinic dedicated;\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Patients with uncertain histopathological findings;\n* Patients with persistent or active Helicobacter pylori infection;\n* Patients with long-term proton pump inhibitor users and atrophic pangastritis","18 Years",{"count":53,"type":21},600,"Autoimmune atrophic gastritis (AAG) is an immune-mediated disorder characterized by the loss of oxyntic glands and mucosal atrophy1.Specific autoantibodies directed to gastric parietal cells (PCA) and\u002For to intrinsic factors are inconstantly present1.Despite its morbidity, data on the epidemiology are scant. Its global prevalence has been estimated to be 0.5-4.5%.Hypo-achlorhydria and lack of intrinsic factor lead to malabsorption of many nutrients, as vit. B12, iron and calcium.A damage on elevated turnover cells may develop, affecting hemopoiesis, nervous system, gut, and myocardium, depicting a systemic disease.Moreover, one of the primary function of gastric acidity as a bactericidal defensive barrier is impaired resulting in both gastric and intestinal microbiota modification. It was recently shown that conditions causing hypo-achlorhydria modify the composition of microbiota from stomach to colon. In particular, at colonic level a decrease in the abundance of commensal bacteria associated to a reduction in microbial diversity and an increase of oral bacteria in the stool were shown.The clinical spectrum is unspecific, especially in early stages, leading to substantial diagnostic delay.Patients may be asymptomatic or complain of gastrointestinal manifestations such as atrophic glossitis, malabsorption, diarrhea, and dyspepsia.These symptoms are insufficient for the diagnosis.Neurological and psychiatric symptoms are often overlooked; myocardial infarction due to demand imbalance may occur.Most of AAG manifestations and complications are due to cyanocobalamin deficiency that may be clinically silent for years.Vit. B12 deficiency has also been associated with infertility, very early recurrent miscarriage, failure of assisted reproductive technologies, and neural tube defects.Furthermore, AAG is a preneoplastic condition as may predispose to the development of type I carcinoids and gastric adenocarcinoma.A previous publication of our group on the NH of AAG,showed that all patients evolved into a higher degree of gastric atrophy and\u002For metaplasia; additionally,6.3%of these patients developed a neoplastic complication (median time of 3 yo).These data underlined the need to feel the gap of knowledge in the identification and characterization of the factors promoting neoplastic development or associated with carcinogenesis.Moreover, strategies for prevention and management of non-neoplastic complications and extra-gastrointestinal manifestation have to be better determined Hence, a larger, prospective study looking at this issue is warranted.",[29],"RECRUITING","2026-01-30",{"date":59,"type":36},"2026-02-05",{"date":61,"type":36},"2023-11-17",{"date":63,"type":21},"2026-12-31",{"name":65,"class":43},"Fondazione IRCCS Policlinico San Matteo di Pavia",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":66},"100377209","the-gastric-precancerous-conditions-study-100377209","NCT04191551","The GAstric Precancerous Conditions Study","GAPS","Inclusion Criteria: Subjects between the ages of 35 and 84, who are undergoing outpatient endoscopy for the following indications are eligible: abdominal pain, dyspepsia, iron deficiency anemia, Helicobacter assessment, surveillance of suspected or known intestinal metaplasia, evaluation for family history of gastric cancer\n\nExclusion Criteria:\n\n* Cannot give consent\n* Have history of gastric surgery\n* Have history of solid tumor or bone marrow transplant\n* Platelet Count \\\u003C 70 or international normalized ratio \\> 1.5","35 Years","84 Years",{"count":53,"type":21},"Gastric cancer afflicts 27,000 Americans annually and carries a dismal prognosis. One reason for poor outcomes is late diagnosis, as the majority of gastric cancers in the United States are diagnosed at a relatively advanced stage where curative resection is unlikely. Gastric precursors (such as atrophic gastritis and intestinal metaplasia) are precancerous changes to the stomach mucosa which increases risk for subsequent gastric cancer.\n\nThe Gastric Precancerous Conditions Study (GAPS) is an observational study of patients at elevated risk for gastric cancer. Investigators seek to recruit patients from endoscopy unit of Stanford Health Care, a large academic network of hospitals and clinics serving Northern California. Investigators will recruit patients who are both symptomatic (e.g. dyspepsia) and asymptomatic (e.g. referred for screening), and individuals both with known precursor lesions (such as intestinal metaplasia) or at high risk for carrying precursor lesions. A component of the study is long-term follow-up of individuals with gastric precursors. This is to understand their risk factors for histologic progression and regression. During both index and subsequent endoscopies, the study team will collect biospecimens (e.g. blood, saliva, gastric tissue).",[79,80,81,29],"Gastric Cancer","Intestinal Metaplasia of Gastric Mucosa","Helicobacter Pylori Infection","2025-12-13",{"date":84,"type":36},"2025-12-16",{"date":86,"type":36},"2018-07-30",{"date":88,"type":21},"2028-06-30",{"name":90,"class":43},"Stanford University",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":66},"100212860","phase-4-multicentric-randomized-study-of-h-pylori-eradication-and-pepsinogen-testing-for-prevention-of-gastric-cancer-mortality-100212860","NCT02047994","Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality","GISTAR","Inclusion Criteria:\n\n* Men and women aged 40-64 at the time of signing the consent form\n* Willingness to get involved in the study irrespective in which of the study arms (after detailed information on the potential benefits and risks that this study may confer)\n* The person has signed a consent form (including the acceptance of transporting the samples over the borders, as appropriate)\n* To be in good health, as determined by a physical examination and history performed by a study physician at enrolment\n\nExclusion Criteria:\n\n* Personal history of gastric cancer (prevalent gastric cancer cases will not be revealed at the time of inclusion, and therefore will be included)\n* Gastric resections due to benign disease (ulcer suturing and vagotomy are accepted)\n* H. pylori eradication therapy within 12 months prior to inclusion (irrespective of the treatment result)\n* Presence of alarm symptoms for digestive or any other diseases (detailed in the questionnaire or during the physician evaluation)\n* Pathological findings at physical investigation suggestive for a serious organic disease (physician evaluation)\n* Serious co-morbid condition with life expectancy less than 5 years (physician evaluation)\n* Factors otherwise limiting the participation according to the protocol conditions (problems of mobility, etc.)\n* Serious psychological conditions\u002Fpsychiatric disease limiting the possibilities to understand the requirements for diagnostic and\u002For medical interventions (physician evaluation)\n* Low expectations on the compliance for the diagnostic work-up or treatment (physician evaluation)\n* Expected loss for the follow-up (e.g. lack of communication possibilities and data entry in the registries, expected travel abroad, etc.) (physician evaluation)\n* Signed consent form is not available","64 Years",{"count":100,"type":21},30000,"INTERVENTIONAL",[103],"PHASE4","Currently no ideal preventive modalities are available for reducing gastric-cancer caused mortality in organized population-based application. The primary objective of the study is to determine if H.pylori screening followed by eradication of positive subjects and endoscopic follow-up of those with serological evidence of atrophic gastritis reduces mortality from gastric cancer in middle-aged people in high-risk areas. The GISTAR study is a multicenter randomized study of H.pylori eradication and pepsinogen testing for prevention of gastric cancer mortality. Altogether 30.000 individuals aged 40-64 years will be enrolled, providing 90% study power to detect at least 35% reduction in gastric cancer mortality at 15 years of follow-up. Participants will be randomly allocated to one of two groups. In the active investigation\u002Fmanagement group those positive for H.pylori will be offered eradication therapy and individuals with decreased pepsinogen I\u002FII ratio will be invited for endoscopy. The control group will receive standard health care. The primary endpoint for this trial will be the mortality difference from gastric cancer between the two groups at 15 years or when enough cases accumulate to demonstrate a statistical difference. The study is expected to provide valuable information on the utility for reduction in gastric cancer mortality of: 1) H.pylori eradication in adults on a population-basis, including subjects who may already have pre-malignant lesions; and 2) pepsinogen testing in screening settings. A pilot study of 3,455 individuals prior to the main trial was conducted from October 2013 to December 2016.",[106,29,79],"Helicobacter Pylori Infections",[108,109,110,111,112,113],"Gastric cancer","Gastric cancer mortality","Helicobacter pylori treatment","Pepsinogen testing","Endoscopy","Volatile marker","2025-04-30",{"date":116,"type":36},"2025-05-02",{"date":118,"type":36},"2013-03",{"date":120,"type":21},"2035-12",{"name":122,"class":43},"International Agency for Research on Cancer",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100573817","observation-on-the-efficacy-of-radiofrequency-ablation-for-patients-with-moderate-to-severe-gastric-atrophy-with-enterosis-with-or-without-atrophy-of-intraepithelial-neoplasia-an-observational-study-100573817","NCT06751212","Observation on the Efficacy of Radiofrequency Ablation for Patients With Moderate to Severe Gastric Atrophy With Enterosis With or Without Atrophy of Intraepithelial Neoplasia: An Observational Study","Inclusion Criteria:\n\n* Age 18-70 years old, male or female.\n* Patients who had undergone gastroscopy within 3 months prior to inclusion, and whose histologic diagnosis of chronic gastritis was histologically atrophic enterocolitis graded at moderate-to-severe with or without low-grade intraepithelial neoplasia.\n* Patients who had undergone gastroscopy within 3 months prior to inclusion, and whose OLGA (atrophic grading and staging criteria for chronic gastritis) or OLGIM (enteric grading and staging criteria for chronic gastritis) staging criteria had reached moderately severe.\n* Helicobacter pylori negative.\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* Previous history of malignant tumors of the digestive tract or history of gastrointestinal surgery.\n* Malignant tumors of other organs, coagulation disorders, cardiopulmonary insufficiency, hepatic and renal insufficiency, etc.\n* Those who are unable or unwilling to sign the informed consent form.","70 Years",{"count":131,"type":21},62,"The aim of this observational study was to understand the effect of radiofrequency ablation on subjects with moderate to severe gastric atrophy with enterocolitis with or without low-grade intraepithelial neoplasia who underwent radiofrequency ablation. The main question it aims to answer is:\n\nDoes radiofrequency ablation therapy reduce gastric mucosal atrophy and enterosis in subjects with moderate to severe gastric atrophy with enterosis with or without low-grade intraepithelial neoplasia?",[29],"2024-12-26",{"date":136,"type":36},"2024-12-27",{"date":138,"type":21},"2024-12-31",{"date":140,"type":21},"2028-03-30",{"name":142,"class":43},"Xiuli Zuo",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":129,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":66},"100531709","atrophic-gastritis-predicts-the-risk-of-gastric-cancer-100531709","NCT06203327","Atrophic Gastritis Predicts the Risk of Gastric Cancer","Atrophic Gastritis Predicts the Risk of Gastric Cancer: a Prospective Cohort Study","Inclusion Criteria:\n\n* Ability and willingness to participate in the study and to sign and give informed consent\n* Biopsies were collected based on the recommendation of updated Sydney system\n\nExclusion Criteria:\n\n* under 18 or over 80 years old\n* history of gastrectomy\n* severe systemic diseases or malignancy",{"count":151,"type":21},2042,"Despite declining incidence rates, gastric cancer (GC) ranks the fourth leading cause of cancer-related mortality and the fifth most common cancer worldwide, with the highest incidence reported in Eastern Asia. The 5-year overall survival rate of early GC exceeds 90%, which was well above advanced GC. Most intestinal-type GCs follow the Correa cascade-inflammation,atrophy, intestinal metaplasia (IM), dysplasia and subsequent carcinoma. The presence of gastric mucosal atrophy and intestinal metaplasia are important risk factors for GC. The purpose of this study was to investigate the incidence of GC attributed to atrophic gastritis in a region with high incidence of GC.",[29],[29,79],{"date":156,"type":36},"2024-12-30",{"date":158,"type":36},"2023-12-15",{"date":160,"type":21},"2034-12-31",{"name":162,"class":43},"Shanghai Jiao Tong University School of Medicine",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":169,"targetDuration":171,"studyType":23,"phases":4,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":185},"100443403","helicobacter-pylori-atrophic-gastritis-and-intestinal-metaplasia-registry-and-prospective-study-100443403","NCT05053945","Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study","Inclusion Criteria:\n\n* Adults \\>= 18 years of age\n* Written informed consent obtained\n* Diagnosed with current or past H. pylori infection,\n* Histologically proven atrophic gastritis (body and\u002For antrum of stomach), intestinal metaplasia (complete and incomplete), dysplasia (any grade) and\u002For gastric cancer (post- treatment)\n\nExclusion Criteria:\n\n* Co-morbid illness that prohibit endoscopic surveillance\n* Declines for study questionnaire, biobanking of specimens and\u002For regular review per study protocol",{"count":170,"type":21},260,"3 Years","Since much is unknown about factors that lead to progression of the pre-neoplastic lesions and cancer. In addition, there is ongoing debate on the optimal surveillance intervals and techniques. To solve these important clinical questions, the establishment of a registry for a longitudinal study is planned.",[174,29,175],"Helicobacter Pylori","Intestinal Metaplasia","2024-08-28",{"date":178,"type":36},"2024-08-29",{"date":180,"type":36},"2020-05-15",{"date":182,"type":21},"2025-12-31",{"name":184,"class":43},"Chinese University of Hong Kong",2,{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":204,"locationsCount":66},"100426980","prediction-of-gastric-cancer-in-intestinal-metaplasia-and-atrophic-gastritis-100426980","NCT04840056","Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis","Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis - Application of Artificial Intelligence in Histology and Clinical Data","GIMA","Inclusion Criteria:\n\n* Adults \\>= 18 years of age\n* Histologically proven atrophic gastritis or intestinal metaplasia (at antrum and\u002For body and\u002For angular of stomach)\n\nExclusion Criteria:\n\n\\- none",{"count":195,"type":21},1300,"The primary objectives of this study are:\n\n* To identify clinical or histological factors associated with gastric cancer development in patients with IM and AG\n* To establish a machine learning algorithm for prediction of future gastric cancer risks and individual risk stratification in patient with IM and AG",[79,175,29],[199],"artificial intelligence",{"date":178,"type":36},{"date":202,"type":36},"2021-04-15",{"date":182,"type":21},{"name":184,"class":43},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":212,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":101,"phases":215,"briefSummary":217,"conditions":218,"keywords":220,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":232,"locationsCount":66},"100409598","surveillance-of-premalignant-stomach---individualized-endoscopic-follow-up-100409598","NCT04613570","SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up","SUPREME","Inclusion Criteria:\n\n* Patients scheduled for upper GI endoscopy with indication for gastric biopsies, including those with known gastric pathology (e.g. auto-immune gastritis) or premalignant conditions (e.g patients under surveillance because of atrophic gastritis);\n* Age above 45 years old\n\nExclusion Criteria:\n\n* History of previous gastrectomy;\n* History of endoscopic resection of neoplastic lesion\n* History of previous gastric dysplasia (even with no detectable lesion)\n* Hereditary syndromes that increase gastric cancer risk (familial adenomatous polyposis; Lynch syndrome)\n* Serious comorbidities (ASA 3 or more)\n* Medication with anticoagulants","45 Years",{"count":214,"type":21},912,[216],"NA","Introduction: Gastric atrophy and intestinal metaplasia are the principal precursors for gastric cancer and, therefore, are considered gastric premalignant conditions. Although current guidelines recommend surveillance of individuals with these conditions, the best method for its identification and staging (histological vs endoscopy) and the best time schedule for follow-up are still controversial. Aims: To describe for the first-time patients with premalignant conditions both clinically (familial history), histologically (OLGA\u002FOLGIM; complete\u002Fincomplete metaplasia) and endoscopically (EGGIM) using validated scales and to describe evolution of these parameters through time. To estimate prospectively the gastric cancer risk according to EGGIM stages. To define the best endoscopic surveillance follow-up for the several stages considering clinical, histological and endoscopic factors.\n\nMethods: Multicenter study involving different gastroenterology departments from several countries. Consecutive patients older than 45 years scheduled for upper endoscopy in each of these centers will be evaluated by High-Resolution- endoscopy with virtual chromoendoscopy and EGGIM will be calculated. Guided biopsies (if areas suspicious of IM) and\u002For random biopsies (if no areas suspicious of IM) in antrum and corpus will be made and OLGA\u002FOLGIM stages calculated. Patients will be evaluated in clinical consultation and database will be fulfilled. All patients will be eradicated for Helicobacter pylori infection if positive. At that occasion, all the patients with EGGIM\\>5 and\u002For OLGA III\u002FIV and\u002For OLGIM III\u002FIV will be randomized for yearly (12 to 16 months) or every three years (32-40 months) endoscopic follow-up during a period of 6 years (SUPREME I). Endoscopic observational follow-up will be scheduled for patients with EGGIM 1-4 and OLGIM I\u002FII at 3 and 6 years (SUPREME II). For individuals with no evidence of IM (EGGIM 0 and OLGIM 0, OLGA 0-II) a follow-up endoscopy 6 years after will be proposed (SUPREME III).",[29,175,219,79],"Gastric Dysplasia",[221,222,223,224,225],"atrophic gastritis","gastric cancer","intestinal metaplasia","gastric dysplasia","surveillance","2022-03-29",{"date":228,"type":36},"2022-03-31",{"date":230,"type":36},"2021-01-02",{"date":63,"type":21},{"name":233,"class":43},"Instituto Portugues de Oncologia, Francisco Gentil, Porto",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":263},"100364198","screening-of-gastric-cancer-via-breath-volatile-organic-compounds-by-hybrid-sensing-approach-100364198","NCT04022109","Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach","VOGAS","Inclusion Criteria:\n\n* Patients with verified gastric cancer (Group 1 \\& 2)\n* Patients undergoing or having undergone upper endoscopy according to clinical indications (Group 3 \\& 5)\n* Average-risk population group aged 40-64 at inclusion without alarm symptoms (Group 4)\n* Motivation to participate in the study\n* Physical status allowing volatile marker sampling and other procedures within the protocol\n* Signed consent\n\nExclusion Criteria:\n\n* Known other active cancer\n* Ventilation problems, airway obstruction\n* Unwillingness or inability to co-operate",{"count":242,"type":21},5000,"The study is aimed to determine the potential of volatile marker testing for gastric cancer screening.\n\nThe study will be addressing the role of confounding factors, including lifestyle factors, diet, smoking as well as addressing the potential role of microbiota in the composition of exhaled volatile markers.",[79,29,219,245],"H.Pylori Infection",[247,248,108,249,250,251,252,253],"Volatile organic compounds","Breath testing","Atrophic gastritis","Precancerous lesions","Screening","Nanosensor technology","GC-MS","2021-07-19",{"date":256,"type":36},"2021-07-26",{"date":258,"type":36},"2019-11-01",{"date":260,"type":21},"2026-12",{"name":262,"class":43},"University of Latvia",5]